FDA 483 - Naseem A. Jaffrani, M.D. - March 13, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Naseem A. Jaffrani MD, Clinical Investigator, revealed significant non-compliance in clinical research studies. The firm failed to promptly report serious and non-serious adverse events, did not conduct investigations according to the plan, and maintained inadequate and inaccurate case histories. Additional deficiencies included improper informed consent documentation, unapproved changes by the Institutional Review Board, and insufficient investigational drug disposition records.
ID · 2131b5ce-2494-4de0-8724-a136e9945fbd